Intravenous immunoglobulin a natural regulator of immunity and inflammation.
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 25 years. IVIG products are also effective in the treatment of autoimmune and inflammatory disorders; however, the precise mechanism(s) of action is not known. Recent investigations suggest that IVIG has a much broader ability to regulate cellular immunity including innate and adaptive components. IVIG is also a recently recognized modifier of complement activation and injury. Here, we discuss these important advancements and how this knowledge applies to desensitization protocols and to the treatment of antibody-mediated rejection.
Jordan
Stanley C
SC
Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. sjordan@cshs.org
Toyoda
Mieko
M
Vo
Ashley A
AA
D000818:Animals; D003167:Complement Activation / Q000187:drug effects; D003888:Desensitization, Immunologic / Q000379:methods*; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007113:Immunity, Innate / Q000187:drug effects; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D023001:Transplantation Tolerance / Q000187:drug effects; D014184:Transplantation, Homologous
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors